세계의 장 질환 검사 시장 : 규모, 점유율 및 동향 분석(질환별, 지역별), 부문별 예측(2025-2030년)

Enteric Disease Testing Market Growth & Trends:

The global enteric disease testing market size is anticipated to reach USD 4.74 billion by 2030 and is anticipated to expand at a CAGR of 3.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing incidence of enteric diseases and the rising adoption of advanced diagnostic technologies are the major factors contributing to market growth. According to the U.S. Center for Disease Control and Prevention, nearly 11 and 21 million cases of typhoid fever and approximately 5 million paratyphoid fever cases are recorded worldwide each year.

The increasing incidence of gastrointestinal infections in multiple regions, driven by changing lifestyles and consumer preferences, has generated greater demand for enteric disease testing solutions. Growing awareness regarding the severe effects of enteric diseases, if not intervened in time, has led to the rising number of tests. The focus of multiple government agencies on protecting public health and preventing outbreaks is also expected to drive the growth of this industry in the coming years.

Government initiatives for improved healthcare, including screening programs, awareness campaigns, and specific welfare schemes, are projected to fuel market growth. For instance, in the U.S., the Centers for Disease Control and Prevention (CDC) uses the System for Enteric Disease Response, Investigation, and Coordination (SEDRIC) to ensure efficient surveillance and response to disease outbreaks linked to food or animal contact. It also helps manage the BEAM (Bacteria, Enterics, Ameba, and Mycotics) Dashboard, which provides enteric disease outbreak data to public viewers. Such initiatives are expected to result in increased testing in the forecast period.

Enteric Disease Testing Market Report Highlights:

• The bacterial segment dominated the enteric disease testing market with nearly 60% share in 2024 owing to many bacteria, such as C. difficile, E. coli, Shigella, and Salmonella, which cause common enteric diseases.
• The parasitic segment is expected to experience growth due to increasing cases of enteric diseases driven by contaminated water and food, poor sanitation systems in various regions, and lack of adequate hygiene.
• The growing focus of multiple governments on offering improved healthcare services that feature advanced diagnostic technologies to prevent large-scale outbreaks is expected to create growth opportunities.
• North America dominated the global industry in 2024 owing to factors such as a robust healthcare infrastructure and the presence of key diagnostic technology developers and biotechnology companies.
• Preventive measures embraced by local agencies and government-funded research programs are anticipated to fuel growth.
• In February 2025, BIOMERIEUX announced that it received clearance from the U.S. FDA for its new testing solution, BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Disease Outlook
  • 1.2.2. Regional Scope
  • 1.2.3. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Disease Outlook
  • 2.2.2. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Enteric Diseases Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Enteric Diseases Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Enteric Diseases Testing: Disease Estimates & Trend Analysis

• 4.1. Disease Segment Dashboard
• 4.2. Enteric Diseases Testing Market: Industry Movement Analysis
• 4.3. Global Enteric Diseases Testing Market Size & Trend Analysis, by Disease , 2018 to 2030 (USD Million)
• 4.4. Bacterial
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. C. Difficile
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Campylobacteriosis
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Cholera
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. E. Coli
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. H. Pylori
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.7. Salmonellosis
    • 4.4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.8. Shigellosis
    • 4.4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Viral
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.2. Rotavirus
    • 4.5.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5.3. Norovirus
    • 4.5.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Parasitic
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.2. Amebiasis
    • 4.6.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.3. Cryptosporidiosis
    • 4.6.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6.4. Giardiasis
    • 4.6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Enteric Diseases Testing Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Dashboard
• 5.2. Regional Market Share Analysis, 2024 & 2030
• 5.3. Continuous bioprocessing market by Region: Key Takeaways
• 5.4. North America
  • 5.4.1. U.S.
    • 5.4.1.1. Key country dynamics
    • 5.4.1.2. Regulatory framework/ reimbursement structure
    • 5.4.1.3. Competitive scenario
    • 5.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.2. Canada
    • 5.4.2.1. Key country dynamics
    • 5.4.2.2. Regulatory framework/ reimbursement structure
    • 5.4.2.3. Competitive scenario
    • 5.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.4.3. Mexico
    • 5.4.3.1. Key country dynamics
    • 5.4.3.2. Regulatory framework/ reimbursement structure
    • 5.4.3.3. Competitive scenario
    • 5.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. Europe
  • 5.5.1. UK
    • 5.5.1.1. Key country dynamics
    • 5.5.1.2. Regulatory framework/ reimbursement structure
    • 5.5.1.3. Competitive scenario
    • 5.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.2. Germany
    • 5.5.2.1. Key country dynamics
    • 5.5.2.2. Regulatory framework/ reimbursement structure
    • 5.5.2.3. Competitive scenario
    • 5.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.3. France
    • 5.5.3.1. Key country dynamics
    • 5.5.3.2. Regulatory framework/ reimbursement structure
    • 5.5.3.3. Competitive scenario
    • 5.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.4. Italy
    • 5.5.4.1. Key country dynamics
    • 5.5.4.2. Regulatory framework/ reimbursement structure
    • 5.5.4.3. Competitive scenario
    • 5.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.5. Spain
    • 5.5.5.1. Key country dynamics
    • 5.5.5.2. Regulatory framework/ reimbursement structure
    • 5.5.5.3. Competitive scenario
    • 5.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.6. Norway
    • 5.5.6.1. Key country dynamics
    • 5.5.6.2. Regulatory framework/ reimbursement structure
    • 5.5.6.3. Competitive scenario
    • 5.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.7. Sweden
    • 5.5.7.1. Key country dynamics
    • 5.5.7.2. Regulatory framework/ reimbursement structure
    • 5.5.7.3. Competitive scenario
    • 5.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5.8. Denmark
    • 5.5.8.1. Key country dynamics
    • 5.5.8.2. Regulatory framework/ reimbursement structure
    • 5.5.8.3. Competitive scenario
    • 5.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Japan
    • 5.6.1.1. Key country dynamics
    • 5.6.1.2. Regulatory framework/ reimbursement structure
    • 5.6.1.3. Competitive scenario
    • 5.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.2. China
    • 5.6.2.1. Key country dynamics
    • 5.6.2.2. Regulatory framework/ reimbursement structure
    • 5.6.2.3. Competitive scenario
    • 5.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.3. India
    • 5.6.3.1. Key country dynamics
    • 5.6.3.2. Regulatory framework/ reimbursement structure
    • 5.6.3.3. Competitive scenario
    • 5.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.4. Australia
    • 5.6.4.1. Key country dynamics
    • 5.6.4.2. Regulatory framework/ reimbursement structure
    • 5.6.4.3. Competitive scenario
    • 5.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.5. South Korea
    • 5.6.5.1. Key country dynamics
    • 5.6.5.2. Regulatory framework/ reimbursement structure
    • 5.6.5.3. Competitive scenario
    • 5.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6.6. Thailand
    • 5.6.6.1. Key country dynamics
    • 5.6.6.2. Regulatory framework/ reimbursement structure
    • 5.6.6.3. Competitive scenario
    • 5.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Latin America
  • 5.7.1. Brazil
    • 5.7.1.1. Key country dynamics
    • 5.7.1.2. Regulatory framework/ reimbursement structure
    • 5.7.1.3. Competitive scenario
    • 5.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7.2. Argentina
    • 5.7.2.1. Key country dynamics
    • 5.7.2.2. Regulatory framework/ reimbursement structure
    • 5.7.2.3. Competitive scenario
    • 5.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. MEA
  • 5.8.1. South Africa
    • 5.8.1.1. Key country dynamics
    • 5.8.1.2. Regulatory framework/ reimbursement structure
    • 5.8.1.3. Competitive scenario
    • 5.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.2. Saudi Arabia
    • 5.8.2.1. Key country dynamics
    • 5.8.2.2. Regulatory framework/ reimbursement structure
    • 5.8.2.3. Competitive scenario
    • 5.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.3. UAE
    • 5.8.3.1. Key country dynamics
    • 5.8.3.2. Regulatory framework/ reimbursement structure
    • 5.8.3.3. Competitive scenario
    • 5.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8.4. Kuwait
    • 5.8.4.1. Key country dynamics
    • 5.8.4.2. Regulatory framework/ reimbursement structure
    • 5.8.4.3. Competitive scenario
    • 5.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Recent Developments & Impact Analysis, By Key Market Participants
• 6.2. Company/Competition Categorization
• 6.3. Vendor Landscape
  • 6.3.1. Key company heat map analysis, 2024
• 6.4. Company Profiles
  • 6.4.1. Abbott
    • 6.4.1.1. Company overview
    • 6.4.1.2. Financial performance
    • 6.4.1.3. Product benchmarking
    • 6.4.1.4. Strategic initiatives
  • 6.4.2. BD
    • 6.4.2.1. Company overview
    • 6.4.2.2. Financial performance
    • 6.4.2.3. Product benchmarking
    • 6.4.2.4. Strategic initiatives
  • 6.4.3. Biomerica
    • 6.4.3.1. Company overview
    • 6.4.3.2. Financial performance
    • 6.4.3.3. Product benchmarking
    • 6.4.3.4. Strategic initiatives
  • 6.4.4. BIOMERIEUX
    • 6.4.4.1. Company overview
    • 6.4.4.2. Financial performance
    • 6.4.4.3. Product benchmarking
    • 6.4.4.4. Strategic initiatives
  • 6.4.5. Bio-Rad Laboratories, Inc.
    • 6.4.5.1. Company overview
    • 6.4.5.2. Financial performance
    • 6.4.5.3. Product benchmarking
    • 6.4.5.4. Strategic initiatives
  • 6.4.6. Cepheid
    • 6.4.6.1. Company overview
    • 6.4.6.2. Financial performance
    • 6.4.6.3. Product benchmarking
    • 6.4.6.4. Strategic initiatives
  • 6.4.7. Coris Bioconcept
    • 6.4.7.1. Company overview
    • 6.4.7.2. Financial performance
    • 6.4.7.3. Product benchmarking
    • 6.4.7.4. Strategic initiatives
  • 6.4.8. DiaSorin S.p.A.
    • 6.4.8.1. Company overview
    • 6.4.8.2. Financial performance
    • 6.4.8.3. Product benchmarking
    • 6.4.8.4. Strategic initiatives
  • 6.4.9. Meridian Bioscience
    • 6.4.9.1. Company overview
    • 6.4.9.2. Financial performance
    • 6.4.9.3. Product benchmarking
    • 6.4.9.4. Strategic initiatives
  • 6.4.10. Quest Diagnostics Incorporated
    • 6.4.10.1. Company overview
    • 6.4.10.2. Financial performance
    • 6.4.10.3. Product benchmarking
    • 6.4.10.4. Strategic initiatives